San Francisco startup Composition Therapeutics can be engaged on an oral, once-daily GLP-one drug named GSBR-1290—the drug surpassed Wall Avenue’s anticipations in June any time a mid-stage review confirmed ordinary weight loss of all over 6% and it designs to get started on another mid-stage trial towards the end of this year—that founder an… Read More